CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,305 | -23.3% | 72,830 | -5.1% | 0.01% | -22.2% |
| Q2 2023 | $4,310 | +15.3% | 76,763 | -7.1% | 0.01% | 0.0% |
| Q1 2023 | $3,737 | -1.5% | 82,626 | -11.5% | 0.01% | -10.0% |
| Q4 2022 | $3,794 | -99.9% | 93,341 | +17.8% | 0.01% | -33.3% |
| Q3 2022 | $5,180,000 | -32.5% | 79,257 | -37.2% | 0.02% | -25.0% |
| Q2 2022 | $7,673,000 | +7.2% | 126,259 | +10.7% | 0.02% | +33.3% |
| Q1 2022 | $7,160,000 | -9.2% | 114,061 | +9.6% | 0.02% | -16.7% |
| Q4 2021 | $7,884,000 | -26.9% | 104,046 | +8.0% | 0.02% | -33.3% |
| Q3 2021 | $10,785,000 | -36.0% | 96,352 | -7.5% | 0.03% | -32.5% |
| Q2 2021 | $16,862,000 | +16.2% | 104,159 | -12.5% | 0.04% | +2.6% |
| Q1 2021 | $14,510,000 | – | 119,081 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |